share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K:外国发行人报告(业绩相关)
美股SEC公告 ·  2024/08/17 04:09

Moomoo AI 已提取核心信息

NeuroSense Therapeutics has entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on August 16, 2024, enabling the company to offer and sell ordinary shares with aggregate gross proceeds of up to $2.52 million. The offering will be made under the company's existing shelf registration statement on Form F-3.Under the agreement, JonesTrading will serve as the sales agent, receiving a 3.0% commission on gross proceeds. The shares will be sold through various methods including at-the-market offerings on Nasdaq Capital Market or negotiated transactions at prevailing market prices. The company maintains flexibility with no obligation to sell shares.The agreement includes customary terms and conditions, with sales terminating upon either party's termination or mutual agreement. The offering is subject to satisfaction of certain conditions and will be conducted in compliance with applicable securities laws and regulations.
NeuroSense Therapeutics has entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on August 16, 2024, enabling the company to offer and sell ordinary shares with aggregate gross proceeds of up to $2.52 million. The offering will be made under the company's existing shelf registration statement on Form F-3.Under the agreement, JonesTrading will serve as the sales agent, receiving a 3.0% commission on gross proceeds. The shares will be sold through various methods including at-the-market offerings on Nasdaq Capital Market or negotiated transactions at prevailing market prices. The company maintains flexibility with no obligation to sell shares.The agreement includes customary terms and conditions, with sales terminating upon either party's termination or mutual agreement. The offering is subject to satisfaction of certain conditions and will be conducted in compliance with applicable securities laws and regulations.
NeuroSense Therapeutics于2024年8月16日与JonesTrading Institutional Services LLC签署了一项按需资本™销售协议,使公司能够提供和出售普通股,筹集总收益高达252万美元。此次发行将根据公司的现有F-3表格柜注册声明进行。根据协议,JonesTrading将担任销售代理,获得总收益的3.0%佣金。股票将通过包括在纳斯达克资本市场的市场发行或根据当前市场价格的谈判交易等多种方式出售。公司保持灵活性,无义务出售股票。该协议包括惯例条款和条件,销售将在任何一方终止或双方达成一致时终止。此次发行需要满足某些条件,并将遵循适用的证券法律法规进行。
NeuroSense Therapeutics于2024年8月16日与JonesTrading Institutional Services LLC签署了一项按需资本™销售协议,使公司能够提供和出售普通股,筹集总收益高达252万美元。此次发行将根据公司的现有F-3表格柜注册声明进行。根据协议,JonesTrading将担任销售代理,获得总收益的3.0%佣金。股票将通过包括在纳斯达克资本市场的市场发行或根据当前市场价格的谈判交易等多种方式出售。公司保持灵活性,无义务出售股票。该协议包括惯例条款和条件,销售将在任何一方终止或双方达成一致时终止。此次发行需要满足某些条件,并将遵循适用的证券法律法规进行。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息